Sabby Management’s Galectin Therapeutics GALT Stock Holding History

Sabby Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-14,029	Closed	-$89K	–	135
2018 Q2	$89K	Sell	14,029 -129,371	-90%	-$630K	0.01%	115
2018 Q1	$680K	Buy	+143,400	New	+$668K	0.08%	85
2016 Q4	–	Sell	-87,999	Closed	-$78.2K	–	310
2016 Q3	$99K	Sell	87,999 -574,468	-87%	-$1.02M	﹤0.01%	291
2016 Q2	$974K	Sell	662,467 -410,298	-38%	-$602K	0.05%	162
2016 Q1	$1.53M	Sell	1,072,765 -13,850	-1%	-$18.6K	0.08%	123
2015 Q4	$1.78M	Buy	+1,086,615	New	+$2.49M	0.1%	133
2015 Q1	–	Sell	-15,842	Closed	-$55	–	307
2014 Q4	$55	Buy	+15,842	New	+$70K	﹤0.01%	226

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Sabby Management's GALT Position: Q3 2018 in Review

Sabby Management sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 14,029 shares — an estimated $89K sold.

Sabby Management first reported a position in GALT in Q4 2014 and held it in 7 quarters. The position peaked at $1.78M in Q4 2015. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

Sabby Management reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
Sabby Management sold 14,029 Galectin Therapeutics shares in Q3 2018, an estimated $89K.
Sabby Management first reported a position in Galectin Therapeutics in Q4 2014 and held it in 7 quarters.
Sabby Management's Galectin Therapeutics position peaked at $1.78M in Q4 2015.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.